Title: International Financial Reporting Standards
1International Financial Reporting Standards
Presentation to Analysts and Investors 6 April
2005
2Cautionary statement
- International Financial Reporting Standards
(IFRS) are being applied in the European Union
for the first time. There are a number of new
and revised Standards included within the body of
Standards that comprise IFRS. There is not yet a
significant body of established practice upon
which to draw in forming opinions regarding their
interpretation and application. Accordingly,
practice is continuing to evolve. At this
preliminary stage, therefore, the full financial
effect of reporting under IFRS, as it will be
applied and reported on in the Groups first IFRS
financial statements, cannot be determined with
certainty and may be subject to change. - The purpose of this presentation is to provide
information on the expected impact of the
adoption of IFRS. The unaudited financial
information which follows represents our current
view and may be impacted by changes in the
business or to IFRS or the interpretation
thereof. This presentation should be treated
with appropriate caution and should not be relied
upon.
3Agenda
- Overview
- Development costs
- Share-based payments
- Financial instruments
- Business combinations
- Income taxes
- Other issues
- QA
4Overview
- IFRS represents a change in accounting not cash
flows - Generally a move to more fair value accounting
- this may generate greater volatility
- The Standards that will have the most impact on
Misys are - IAS 38 Intangible Assets - capitalisation of
development costs - IFRS 2 Share-based Payment
- IFRS 3 Business Combinations - goodwill
accounting - IAS 39 Financial Instruments Recognition and
Measurement - IAS 12 Income Taxes
- The detailed interpretation of certain areas of
the new Standards is still subject to debate
within the accounting community
5Annualised impact on profit
m
Removal of goodwill amortisation
50 - 55
Net effect of ongoing capitalised development
costs
5 - 10
Current year EMR / CPR incremental spend
5
10 - 15
Net effect of capitalised development costs (note
1)
Incremental charge for share-based payments
(7) - (10)
Taxation
(2) - (5)
Annualised incremental effect on profit excluding
goodwill amortisation (note 2)
(2) - 3
Note 1 Capitalisation of development costs is
still subject to ongoing review and audit. Given
the relatively steady growth in RD expenditure
over recent years on a like for like basis the
impact on the Income Statement is expected to be
a credit of 5m-10m pa plus the impact of the
anticipated additional spend on EMR and CPR
(expected to be 5m for year ending 31 May
2005) Note 2 Unaudited and subject to the
resolution of outstanding issues including
capitalisation of development costs
Like for like data excludes the impact of
acquisitions and disposals and is stated at
constant exchange rates.
6Development costs
- Issue
- Under IFRS development costs must be capitalised
when the future technical feasibility and
economic benefit of the asset can be demonstrated - Under UK GAAP prudence was the overriding
principle which resulted in all expenditure being
expensed - Many industries like our own will therefore have
to capitalise significant development costs which
are currently expensed as incurred
7IAS 38 Intangible assets
Development costs
- Under IAS 38 an intangible asset arises from
development if, and only if, all of the following
can be demonstrated - technical feasibility of completing
- intention to complete and the intention and
ability to use or sell the intangible asset - how the intangible asset will generate probable
future economic benefits - the availability of adequate technical, financial
and other resources to complete the development
and to use or sell the intangible asset - the ability to measure reliably the expenditure
attributable to the intangible asset during its
development
8Development costs
- Issue
- Under IFRS development costs must be capitalised
when the future technical feasibility and
economic benefit of the asset can be demonstrated - Under UK GAAP prudence was the overriding
principle which resulted in all expenditure being
expensed - Many industries like our own will therefore have
to capitalise significant development costs which
are currently expensed as incurred
- Impact
- Currently all RD expenditure is expensed as
incurred - A significant part of our development costs will
meet the criteria for capitalisation - We are still reviewing this area including
determining appropriate amortisation periods - Given the relatively steady growth in RD
expenditure on a like for like basis over recent
years the net impact on the Income Statement is
expected to be a credit of 5m - 10m pa plus the
impact of the additional spend on EMR and CPR
which is expected to be 5m in the year ending 31
May 2005. The impact on the Balance Sheet will
be more significant.
Like for like data excludes the impact of
acquisitions and disposals and is stated at
constant exchange rates.
9Share-based payments
- Issue
- Share-based payments represent a cost to
businesses which should be reflected by an Income
Statement charge - Charge represents the fair value of the options
granted calculated using an option pricing model - Charge spread over the vesting period
- No share schemes exempt including SAYE and all
employee schemes - Impact likely to be greatest on technology
companies due to share price volatility (higher
cost per option) and number of options granted
- Impact
- Incremental impact on operating profits 7m -
10m pa - Potential volatility of earnings from adjusting
for options that do not vest - Increased charge due to the accounting for share
schemes available to senior management and the
all employee schemes
10Financial instruments
- Issue
- Many financial instruments to be recognised at
fair value on the Balance Sheet - Embedded derivatives must be separately
identified and, where not closely related to the
host contract, separately accounted for - Rules on hedging are more stringent including the
effectiveness of the hedge being assessed at each
Balance Sheet date and determining the ability to
hedge account
- Impact
- Recognition of embedded derivatives may increase
the volatility of earnings in Banking - The effect of accounting for embedded derivatives
will be separately disclosed in our results
announcements - In line with many companies we intend to take
advantage of the transitional rules and only
implement IAS 32 / 39 with effect from 1 June
2005
11Business combinations
- Issue
- Goodwill amortisation replaced by annual
impairment tests - Intangible assets to be separately identified and
disclosed on acquisition, reducing the amount of
goodwill capitalised - Intangibles to be amortised over useful economic
life - All assets and liabilities to be fair valued on
acquisition in accordance with IFRS
- Impact
- No amortisation of goodwill in Income Statement
- IFRS 3 Business Combinations will not be applied
retrospectively to acquisitions made prior to 1
June 2004 - Amortisation of separately identifiable
intangibles resulting from acquisitions made
prior to 1 June 2004 has no significant impact
12Income taxes
- Issue
- IAS 12 looks at temporary differences between
tax and book values for deferred tax whereas UK
GAAP assesses permanent and timing
differences reversing in future periods - The effect on deferred tax of IFRS adjustments
need to be assessed
- Impact
- No impact on cash payments as these remain based
on local rules - Principal effect on Income Statement is the
incremental charge in respect of capitalised
development costs and share-based payments - Deferred tax asset (liability) will arise due to
effect of capitalising development costs - Increased disclosures of current and deferred tax
balances on the Balance Sheet and in the Income
Statement
13Other issues
- Revenue recognition no impact expected from the
transition to IFRS - Early adoption of FRS 17 Retirement Benefits
means minimal impact on pensions - Minimal impact of accruing for holiday pay since
this was already widely accounted for within the
Group - Dividends declared after the Balance Sheet date
are not recognised
14Allowable options
- IFRS 2 Share-based Payment - will be applied
retrospectively in full to provide more
meaningful comparatives - IFRS 3 Business Combinations - will not be
applied retrospectively - IAS 32 / 39 Financial Instruments - will not be
applied to the comparative period (ie year to 31
May 2005) in first full IFRS statements - IAS 19 Employee Benefits - cumulative actuarial
gains and losses on employee post retirement
benefits will be taken to reserves consistent
with the approach adopted under FRS 17
Retirement Benefits
In implementing IFRS for the first time there are
certain optional treatments. The following
treatments will be adopted
15Timetable
- Mandatory for Misys financial year beginning 1
June 2005 - Annual results to 31 May 2005 will be reported
under UK GAAP - Detailed reconciliation of UK GAAP to IFRS for
the year to 31 May 2005 to be provided in Autumn
2005 - Interim results for the six months ending 30
November 2005 reported in January 2006 and the
trading update issued in December 2005 will be
presented in accordance with IFRS
16Balance sheet impact
1 June 2004
m
Net liabilities under UK GAAP as reported
(183)
Removal of dividend liability
21
Removal of goodwill amortisation post 1 June
-
-
Capitalised development costs (note 1)
110
60
-
Deferred taxation
(30)
(15)
Other
(3)
0
-
Net liabilities under IFRS as restated (note 2)
(82) - (120)
Note 1 Capitalisation of development costs is
still subject to ongoing review and audit Note
2 Unaudited and subject to the resolution of
outstanding issues including capitalisation of
development costs
17Annualised impact on profit
m
Removal of goodwill amortisation
50 - 55
Net effect of ongoing capitalised development
costs
5 - 10
Current year EMR / CPR incremental spend
5
10 - 15
Net effect of capitalised development costs (note
1)
Incremental charge for share-based payments
(7) - (10)
Taxation
(2) - (5)
Annualised incremental effect on profit excluding
goodwill amortisation (note 2)
(2) - 3
Note 1 Capitalisation of development costs is
still subject to ongoing review and audit. Given
the relatively steady growth in RD expenditure
over recent years on a like for like basis the
impact on the Income Statement is expected to be
a credit of 5m-10m pa plus the impact of the
anticipated additional spend on EMR and CPR
(expected to be 5m for year ending 31 May
2005) Note 2 Unaudited and subject to the
resolution of outstanding issues including
capitalisation of development costs
Like for like data excludes the impact of
acquisitions and disposals and is stated at
constant exchange rates.
18 QA
19(No Transcript)